Clinical background and outcomes of risk-reducing salpingo-oophorectomy for patients with hereditary breast and ovarian cancer in Japan

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Ovarian Cancer
Breast Cancer
Surgical Oncology
Hereditary Syndromes
Presenter Hidetaka Nomura
Citation Annals of Oncology (2018) 29 (suppl_9): ix79-ix86. 10.1093/annonc/mdy436
Authors H. Nomura1, M. Sekine2, S. Yokoyama3, N. Takeshima1, M. Arai4, S. Nakamura3
  • 1Department Of Gynecology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2Department Of Obstetrics And Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata/JP
  • 3Breast Center, Showa university, Tokyo/JP
  • 4Diagnostics And Therapeutics Of Intractable Diseases, Intractable Disease Center, Juntendo University, Graduate school of medicine, Tokyo/JP



This study aimed to identify the clinical background and treatment outcomes of risk-reducing salpingo-oophorectomy (RRSO) for patients with hereditary breast and ovarian cancer (HBOC) in Japan. This study was supported by the registration committee of the Japanese HBOC Consortium (JHC).


In this retrospective observational study, we examined the database of JHC. This database involves 11,711 patients belonging to 2433 pedigrees.


We analyzed 488 patients diagnosed with HBOC, of which 153 (31.4%) underwent RRSO. These 153 patients comprised88 with BRCA1 mutation carriers (B1), 62 with BRCA2 mutation carriers (B2), and 3 with BRCA1/2 mutation carriers. The mean age of the patients who had not undergone RRSO was 45.2 (range: 21–80) years at the last visit. The mean age of the patients at the time of RRSO was 49.5 (range: 34–69) years. Occult cancer was noted in 4 patients (including 2 B1 and 2 B2 patients). During a mean follow-up period of 2.6 (range: 0–12.6) years, primary peritoneal cancer (PPC) was noted in 1 patient. Comparison of the clinical background of the patients who underwent RRSO and those of age >45 years who did not undergo RRSO revealed that history of breast cancer (p < 0.01), child bearing (p < 0.05), and B1 (p < 0.0001) were significant factors. However, family history of ovarian cancer (p = 0.051) and menopause status were not significantly different.


More than 30% of HBOC have underwent RRSO in Japan. The rates of occult cancer and PPC after RRSO in Japan are the same as those for other countries. Patients with a history of breast cancer and B1 tended to undergo RRSO, while those who did not bear a child tended to avoid RRSO in Japan.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Japanese HBOC Consortium.


Has not received any funding.


All authors have declared no conflicts of interest.